NTLA
Hold up, hold lifted
Intellia just got a very important reset button pressed by the FDA. The agency has lifted its clinical hold on the Phase 3 MAGNITUDE trial for nexiguran ziclumeran, aka nex-z, in adults with ATTR-CM. Translation: enrollment is back on for the global study, and the program is no longer stuck in regulatory purgatory.
Why the pause mattered
This wasn’t some routine paperwork hiccup. The FDA had frozen the trial late last year after a safety scare involving an older patient who developed life-threatening liver damage and later died after receiving the therapy. When a gene-editing drug gets sidelined for a case like that, investors tend to assume the worst and ask all the usual “is the whole thesis broken?” questions.
Why Wall Street cares
For NTLA, nex-z is a flagship shot on goal. A lifted hold doesn’t guarantee smooth sailing from here — safety scrutiny will still be baked into every update like an overprotective parent at prom — but it does mean the asset can keep advancing instead of sitting on the bench.
Big picture
If you own the stock, this is the kind of news that can help rebuild confidence without actually proving the drug works in the real world yet. The next catalyst now shifts from “Will the FDA let this continue?” to “Can Intellia show clean, convincing data from a program that still has to win trust?”